REGENERX BIOPHARMACEUTICALS, INC.: 10-K filed 2016-04-11
What REGENERX BIOPHARMACEUTICALS, INC. reported in its annual report filed 2016-04-11 (fiscal FY 2015): 28 published measures, 58 facts as tagged in accession 0001144204-16-093682.
This filing
- Form
- 10-K (annual report)
- Filed
- 2016-04-11
- Fiscal period
- fiscal FY 2015
- Accession
- 0001144204-16-093682 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All REGENERX BIOPHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-12-31 | 358,223 | USD | |
| At 2014-12-31 | 949,191 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-12-31 | 7,100,619 | USD | |
| At 2014-12-31 | 2,660,810 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-12-31 | -6,742,396 | USD | |
| At 2014-12-31 | -1,711,619 | USD | |
| At 2013-12-31 | -1,621,409 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-12-31 | 317,627 | USD | |
| At 2014-12-31 | 844,043 | USD | |
| At 2013-12-31 | 6,306 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-12-31 | -5,270,483 | USD | 365 |
| 2014-01-01 to 2014-12-31 | -2,753,642 | USD | 365 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-12-31 | 1,076 | USD | 365 |
| 2014-01-01 to 2014-12-31 | 13,320 | USD | 365 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-12-31 | 60,612 | USD | 365 |
| 2014-01-01 to 2014-12-31 | 0 | USD | 365 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-12-31 | -105,074,838 | USD | |
| At 2014-12-31 | -99,804,355 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-12-31 | 0 | USD | 365 |
| 2014-01-01 to 2014-12-31 | 0 | USD | 365 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-12-31 | 10,544 | USD | |
| At 2014-12-31 | 12,871 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-12-31 | 231,607 | USD | 365 |
| 2014-01-01 to 2014-12-31 | 163,432 | USD | 365 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-12-31 | -1,709,535 | USD | 365 |
| 2014-01-01 to 2014-12-31 | -1,555,486 | USD | 365 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-12-31 | 341,927 | USD | |
| At 2014-12-31 | 930,568 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-12-31 | 172,883 | USD | 365 |
| 2014-01-01 to 2014-12-31 | 183,473 | USD | 365 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-12-31 | 359,041 | USD | |
| At 2014-12-31 | 409,619 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-12-31 | 141,130 | USD | |
| At 2014-12-31 | 232,610 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-12-31 | 1,770,147 | USD | 365 |
| 2014-01-01 to 2014-12-31 | 1,555,486 | USD | 365 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-12-31 | 203,185 | USD | 365 |
| 2014-01-01 to 2014-12-31 | 367,275 | USD | 365 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-12-31 | 101,640,092 | shares | |
| At 2014-12-31 | 101,316,580 | shares |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-12-31 | 88,794 | USD | |
| At 2014-12-31 | 85,392 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-12-31 | 5,752 | USD | |
| At 2014-12-31 | 5,752 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-12-31 | 217,911 | USD | |
| At 2014-12-31 | 177,009 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-12-31 | 24,300 | USD | |
| At 2014-12-31 | 86,525 | USD |
Net deferred tax assets
Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-12-31 | 0 | USD | |
| At 2014-12-31 | 0 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-12-31 | 1,566,962 | USD | 365 |
| 2014-01-01 to 2014-12-31 | 1,188,211 | USD | 365 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-12-31 | 3,403 | USD | 365 |
| 2014-01-01 to 2014-12-31 | 4,823 | USD | 365 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-12-31 | 3,403 | USD | 365 |
| 2014-01-01 to 2014-12-31 | 4,823 | USD | 365 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-12-31 | -91,481 | USD | 365 |
| 2014-01-01 to 2014-12-31 | -344,602 | USD | 365 |
Inspect the source
- Entity
- REGENERX BIOPHARMACEUTICALS, INC. / CIK 0000707511
- Captured
- SEC response SHA-256
ffc4eb5988984f6f0271e31d8cf8024b0343b848cad3a73089a36cab28954e4d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000707511.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))